Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene

Cancer Research

Volumn 58, Issue 23, 1998, Pages 5305-5309

  Pérez Díez, Ainhoa ^a   Butterfield, Lisa H ^b   Li, Li ^a   Chakraborty, Nitya G ^a   Economou, James S ^b   Mukherji, Bijay ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; TUMOR ANTIGEN;

ADENOVIRUS; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; EXPRESSION VECTOR; GENE EXPRESSION; GENETIC ENGINEERING; HELPER CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; DENDRITIC CELLS; EPITOPES; EPITOPES, T-LYMPHOCYTE; HUMANS; LYMPHOCYTE ACTIVATION; MELANOMA; NEOPLASM PROTEINS; TRANSDUCTION, GENETIC;

EID: 0032404110     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Boon, T., and van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med., 183: 725-729, 1996.
2. Mukherji, B., Guha, A., Chakraborty, N. G., Sivanandham, M., Nashed, A., Sporn, J. R., and Ergin, M. T. Clonal analysis of cytotoxic and regulatory T cell response in human melanoma. J. Exp. Med., 169: 1961-1976, 1989.
3. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA, 91: 9461-9465, 1994.
4. + T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J. Immunol., 157: 4079-4086, 1996.
5. + CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J. Immunol., 161: 1220-1230, 1998.
6. Kim, C. J., Prevette, T., Cormier, J., Overwijk, W., Roden, M., Restifo, N. P., Rosenberg, S. A., and Marincola, F. M. Dendritic cells infected with poxviruses encoding MART-1/Melan-A sensitize T lymphocytes in vitro. J. Immunother., 20: 276-286, 1997.
7. Tuting, T., Wilson, C. C., Martin, D. M., Kasamon, Y. L., Rowles, J., Ma, D. I., Slingluff, C. L., Jr., Wagner, S. N., van der Bruggen, P., Baar, J., Lotze, M. T., and Storkus, W. J. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-α. J. Immunol., 160: 1139-1147, 1998.
8. Nair, S. K., Boczkowski, D., Morse, M., Cumming, R. I., Lyerly, H. K., and Gilboa, E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotechnol., 16: 364-369, 1998.
9. Liu, M. Transfected human dendritic cells as cancer vaccines. Nat. Biotechnol., 16: 335-336, 1998.
10. Butterfield, L. H., Jilani, S. M., Chakraborty, N. G., Bui, L. A., Ribas, A., Dissette, V. B., Lau, R., Gamradt, S. C., Glaspy, J. A., McBride W. H., Mukherji, B., and Economou, J. S. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a Mart-1 adenovirus. J. Immunol., in press, 1998.
11. Mukherji, B., Wilhelm, S. A., Guha, A., and Ergin, M. T. Regulation of cellular immune response against autologous human melanoma. J. Immunol., 136: 1888-1892, 1986.
12. Ribas, A., Butterfield, L. H., McBride, W. H., Jilani, S. M., Bui, L. A., Vollmer, C. M., Lau, R., Dissette, V. B., Hu, B., Chen, A. Y., Glaspy, J. A., and Economou, J. S. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res., 57: 2865-2869, 1997.
13. Rivoltini, L., Kawakami, Y., Sakaguchi, K., Southwood, S., Sette, A., Robbins, P. F., Marincola, F. M., Salgaller, M. L., Yannelli, J. R., Appella, E., and Rosenberg, S. A. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol., 154: 2257-2265, 1995.
14. Bakker, A. B., Marland, G., De Boer, A. J., Huijbens, R. J., Danen, E. H., Adema, G. J., and Figdor, C. G. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res., 55: 5330-5334, 1995.
15. Van Elsas, A., Van der Burg, S. H., Van der Minne C. E., Borghi, M., Mourer, J. S., Melief, C. J. M., and Schrier, P. I. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen. Eur. J. Immunol., 26: 1683-1689, 1996.
16. Bevan, M. J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med., 143: 1283-1288, 1976.
17. Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (Washington DC), 264: 961-965, 1994.
18. Albert, M. L., Sauter, B., and Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (Lond.), 392: 86-89, 1998.
19. Keene, J. A., and Forman, J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med., 155: 768-782, 1982.
20. - T cells: tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 161: 1122-1134, 1985.
21. Banchereau, J., and Steinman, R. M. Dendritic cells and the control of immunity. Nature (Lond.), 392: 245-252, 1998.
22. Ossendorp, F., Mengede, E., Camps, M., Filius, R., and Melief, C. J. M. Specific T helper requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med., 187: 693-702, 1998.